Hepatitis Treatment News : AbbVie Hep C Combo Cures Nearly All Genotype 1b’s
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hep Newsletter
Join Us:

Back to home » Hepatitis Treatment News » June 2013


June 17, 2013

AbbVie Hep C Combo Cures Nearly All Genotype 1b’s

AbbVie’s investigational triple combination hepatitis C therapy cured an average of 98 percent of those with genotype 1b of the virus. Designated as a “breakthrough therapy” by the U.S. Food and Drug Administration, the direct acting antivirals ABT-450/r, ABT-267 and ABT-333 were studied in various combinations and for various durations both with and without ribavirin among 190 study participants. Investigators presented results from the study at the 23rd Conference of the Asian Pacific Association for the Study of the Liver in Singapore.

The study participants, all of whom had genotype 1b of the virus, were divided into nine groups. One group of 24 treatment-naive participants took the triple combo with ribavirin for eight weeks; 96 percent achieved a sustained virologic response 24 weeks after completing therapy, or SVR, which is considered a cure. Four groups ranging in size between 12 and 25 treatment-naive participants took therapy for 12 weeks: Three groups took ABT-450/r and left out either ABT-267, ABT-333 or ribavirin; and the fourth group took all those drugs. All members of these four groups achieved an SVR. Another group of 25 treatment-naive participants took all the drugs for 24 weeks; 96 percent of them were cured.

Two groups of prior null responders to treatment took therapy for 12 weeks, with one group taking all the drugs, and another taking all drugs but ABT-333. All of these 36 participants were cured. A last group of 16 prior null responders took all the drugs, with 100 percent achieving an SVR 12 weeks after completing therapy and 94 percent doing so 24 weeks after completing therapy.

To read the conference poster, click here.

Search: AbbVie, ABT-450/r, ABT-267, ABT-333, 23rd Conference of the Asian Pacific Association for the Study of the Liver, breakthrough therapy, genotype 1b, hepatitis C, ribavirin.

Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Quick Links
Current Issue
Hep TV
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis C
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
Tell us what you think
Should Medicaid limit access to new hep C drugs?

Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.